NUTM1重排白血病的全面分子与功能分析
NUTM1重排定义了一个显著的B细胞急性淋巴细胞白血病(B-ALL)亚群,尤其在缺乏KMT2A重排的婴儿中。本研究建立NUTM1重排白血病为一种独特实体,具有独特的转录和表观遗传景观,特征为全局DNA低甲基化,与5'融合伴侣无关。功能研究显示NUTM1融合具有双重致癌作用:驱动B淋巴系定向并赋予白血病干细胞特性。表达BRD9-NUTM1融合足以在体内诱导可连续移植的B细胞祖细胞样白血病。机制上,NUTM1融合建立异常染色质状态,全局增强H3K27乙酰化和独特开放染色质区域,协同B系和干性转录程序。与耐药KMT2A重排白血病相反,NUTM1-r白血病细胞对化疗敏感,与对活跃转录的依赖相关。
要点
- NUTM1重排白血病具有全局DNA低甲基化和异常H3K27乙酰化。
- NUTM1融合驱动B系定向并赋予白血病干细胞特性。
- NUTM1-r白血病对化疗敏感,与转录依赖相关。
核心结论
- NUTM1重排白血病是独特的分子实体,具有特定脆弱性,解释其良好临床结局。
研究设计与样本
- 研究通过分子和功能分析,包括体内移植实验,建立NUTM1-r白血病模型。
主要发现
- NUTM1-r白血病显示全局DNA低甲基化,与5'融合伴侣无关。
- NUTM1融合驱动B淋巴系定向并赋予白血病干细胞特性。
- BRD9-NUTM1融合表达足以在小鼠中诱导可连续移植的B细胞祖细胞白血病。
- NUTM1融合建立异常染色质状态,全局增强H3K27乙酰化并创建独特开放染色质区域。
- NUTM1-r白血病细胞对化疗敏感,与对活跃转录的依赖相关。
临床怎么用
- NUTM1-r白血病对化疗敏感,支持其良好临床结局,可考虑调整治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5' fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro-B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.
引用
- Nishimura K, Isobe T, Shigehiro T, et al. Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia. Blood. 2026. PMID: 41460961. doi:10.1182/blood.2024026928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。